AI and Drug Development: IP and data protection challenges - Webinar recording

On Tuesday 19 November, a panel from our London life sciences team presented a webinar on what you need to know when using AI tools in drug development, in order to best protect your invention from an IP perspective, and avoid falling foul of EU and UK data protection laws.

Artificial intelligence (AI) is not new to the life sciences industry but its use in drug development is rapidly growing, as life sciences companies increasingly recognize the benefits of using AI at all stages of the drug development lifecycle.

In this Q&A session, our in-house scientists Marion Palmer and Rachel Gribben discuss the way in which AI is currently being used by the life sciences industry.

Imogen Ireland answers questions on the intellectual property issues arising from using AI in the drug design phase to identify novel compounds for therapeutic uses. For example, whether an AI-derived invention can be patented.

Lilly Taranto answers questions on the challenges from a data protection perspective of using AI tools in the later stages of the drug development lifecycle, from clinical trials through to analysing the success of the drug using patient data.

You can access the recording here

Contacts
Imogen Ireland
Senior Associate
London
Marion Palmer
Senior Scientist
London
Rachel Gribben
Senior Scientist
London

 

This website is operated by Hogan Lovells International LLP, whose registered office is at Atlantic House, Holborn Viaduct, London, EC1A 2FG. For further details of Hogan Lovells International LLP and the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses ("Hogan Lovells"), please see our Legal Notices page. © 2024 Hogan Lovells.

Attorney advertising. Prior results do not guarantee a similar outcome.